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Summary 
Rhododendrol (RD) is a potent tyrosinase inhibitor that is metabolized to RD-quinone by 
tyrosinase, which may underlie the cytotoxicity of RD and leukoderma of the skin that may 
result. We have examined how forced expression of the NAD(P)H quinone dehydrogenase, 
quinone 1 (NQO1), a major quinone-reducing enzyme in cytosol, affects the survival of 
RD-treated cells. We found that treatment of the mouse melanoma cell line B16BL6 or normal 
human melanocytes with carnosic acid, a transcriptional inducer of the NQO1 gene, notably 
suppressed the cell killing effect of RD. This effect was mostly abolished by ES936, a highly 
specific NQO1 inhibitor. Moreover, conditional overexpression of the human NQO1 transgene 
in B16BL6 led to an expression-dependent increase of cell survival after RD treatment. Our 
results suggest that NQO1 attenuates the cytotoxicity of RD and/or its metabolites.  
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Significance 
The cytotoxicity of rhododendrol (RD) against melanin-producing cells is reported to result 
from its metabolite quinone compounds. The NAD(P)H dehydrogenase, quinone 1 (NQO1), a 
major quinone reducing enzyme, is retained at low levels in a basal state in many tissues. 
Treatment of a mouse melanoma cell line or human melanocytes with carnosic acid, an 
established transcriptional inducer of the NQO1 gene, renders cells resistant to RD, and 
inhibition of NQO1 activity eliminates this resistance. Results obtained by conditional 
expression of the human NQO1 transgene in mouse melanoma cells also support the pivotal role 
of NQO1 in detoxification of RD. 
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Running title 
NQO1 mitigates cytotoxicity of rhododendrol 
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Introduction 
Rhododendrol (4-(4-hydroxyphenyl)-2-butanol, RD), a phenolic compound originally isolated 
from the azalea Rhododendron fauriaei, is a strong inhibitor of tyrosinase (Archangelsky 1901; 
Kawaguchi et al. 1942; Akazawa et al. 2006), a key enzyme for melanin biosynthesis that 
catalyzes the oxidation of tyrosine (del Marmol and Beermann 1996). The suppressive effect of 
RD on melanin production has been studied in view of its possible cosmetic applications, and 
subsequently it was added as an ingredient to a commercially available skin lightener produced 
by a cosmetics company in Japan. However, a considerable number of consumers developed 
leukoderma after using the RD-containing skin lightner, and the product was eventually recalled. 
Chemically induced leukoderma is characterized as cutaneous depigmentation caused by 
recurrent exposure to a specific substance that damages epidermal melanin-producing cells 
(Ghosh 2010). As a competitive inhibitor of tyrosinase, RD itself is oxidized by tyrosinase to 
RD-quinone or related compounds, which recent studies suggest are responsible for the 
cytotoxicity of RD and the resulting leukoderma (Ito et al. 2014; Sasaki et al. 2014). 
The NAD(P)H dehydrogenase, quinone 1 (NQO1, also known as DT-diaphorase), catalyzes the 
obligatory two-electron reduction of a range of quinone compounds to their hydroquinone forms, 
thus preventing the one-electron reduction that results in production of potentially harmful 
semiquinone radicals, a source of reactive oxygen species (ROS) (Siegel et al. 2012). 
Depending on the relative toxicity of the parental quinones and their reduced metabolites, 
NQO1 functions as either a detoxifier or a bioactivator for any given quinone compound (Siegel 
et al. 2012). NQO1 gene expression is under the control of the KEAP1/NRF2 transcription 
regulation system, together with genes encoding other phase II detoxification enzymes (Itoh et 
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al. 1997; Kensler et al. 2007). The transcriptional coactivator NRF2 is bound by the E3 
ubiquitin ligase KEAP1 in a basal state, sequestered in the cytosol, and constitutively 
ubiquitinated for proteasome-mediated degradation. In the presence of oxidative and/or 
electrophilic stress, sulfhydryl groups of key cysteine residues of KEAP1 are subjected to 
covalent modification, leading to inhibition of its E3 ligase activity. This results in accumulation 
and subsequent nuclear translocation of NRF2. A heterodimer of NRF2 and a small Maf factor 
binds to the electrophile/antioxidant response element (EpRE/ARE), up-regulating the 
transcription of a set of genes including NQO1 whose products exert a cytoprotective role 
against noxious stress in a coordinated manner. 
In the present study, we investigated how NQO1 activity modulates the cytotoxicity of RD 
against melanin-producing cells. To achieve ectopic overexpression of NQO1, we adopted two 
different approaches. The phytochemical carnosic acid (CA) is oxidized to a electrophilic 
quinone form within cells, which is a potent activator of the KEAP1/NRF2 system (Satoh et al. 
2008). We first explored the effect of CA on proliferation of RD-treated cells, and also 
established and characterized a cell line in which NQO1 expression is conditionally regulated. 
The results obtained from either of these approaches indicated a strong correlation between 
NQO1 expression and resistance to RD. Our observations suggest that the cytotoxicity of RD, 
probably mediated by quinone compounds, can be ameliorated by NQO1, and also that CA, or 
other KEAP1/NRF2 activator chemicals, could have potential cosmetic applications in 
combination with RD. 
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Results 
CA induces expression of NQO1 within the range of concentration for minimal cell killing 
To confirm the effect of CA as a KEAP1/NRF2 activator (Satoh et al. 2008) in our experimental 
setting, we treated B16BL6 mouse melanoma cells with increasing concentrations of CA for 24 
h and examined the cells for expression of NRF2 and one of its targets, NQO1. Although both 
NRF2 and NQO1 were hardly detectable in cells in an uninduced state, addition of CA as well 
as another established NRF2 activator, sulforaphane (Zhang et al. 1992; Zhang et al. 1994), 
clearly increased the cellular amounts of NRF2 and NQO1 in a dose-dependent manner (Figure 
1A). Treatment with 10 µM CA for 24 h, which resulted in quite robust induction of NQO1, 
only marginally compromised cell growth (Figure 1B). Even with 100 µM CA, cell growth was 
at least 70% of non-treated cells. The same concentrations of CA caused similar or slightly 
higher growth inhibition of TERT-immortalized human melanocytes (HEMn-LP/hTERT1, 
Figure 1B). We concluded that treatment with CA in the range of concentration for least toxicity 
elicits firm activation of the KEAP1/NRF2 system and consequent expression of NQO1. 
Recent work has shown that tyrosinase-dependent metabolites of RD have a high propensity for 
linkage with the cysteine residues of cellular proteins, thus inactivating them, which may 
account for at least some of the cytotoxicity of RD (Ito et al. 2015). This prompted us to 
investigate whether RD metabolites activate the KEAP1/NRF2 system by attacking the sensor 
cysteine residues of KEAP1. Contrary to our expectation, however, RD proved to be a much 
poorer activator of NRF2 than CA at the concentration that results in substantial growth 
inhibition (Supplementary Figure S1). 
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CA mitigates cytotoxicity of RD 
We next studied the cytotoxicity of RD in the absence or presence of CA, expecting that NQO1 
expression might modulate the toxicity of the RD-derived quinone compound. First, B16BL6, 
HEMn-LP/hTERT1 or normal human melanocytes (NHEM) were treated with RD alone at 
concentrations of 0 to 2 mM for 24 h, and cell growth was measured. The respective IC50 values 
were 230 μM for B16BL6, 119 μM for NHEM, and 178 μM for HEMn-LP/hTERT1 (Figure 
2A), being comparable to those reported previously for human melanocytes (Sasaki et al. 2014; 
Kasamatsu et al. 2014). When the cells were similarly treated with RD but in the presence of 0.5 
µM CA, the IC50 values increased by 5.5 to >11.2-fold (1260 µM, 840 µM and >2000 µM for 
B16BL6, NHEM, and HEMn-LP/hTERT1, respectively, Figure 2A). Treatment with 10 µM CA 
further increased the IC50 for B16BL6 to >2000 µM, indicating a dose-dependent attenuation 
effect of CA on RD cytotoxicity, which is consistent with the CA dose-dependent expression of 
NQO1 in this range. To demonstrate the pivotal role of NQO1 among dozens of NRF2 targets, 
we added ES936, a highly specific inhibitor for NQO1 (Winski et al. 2001), together with CA 
(Figure 2B). This mostly eliminated the effect of CA, suggesting that NQO1 was solely 
responsible for the CA-mediated dose decrement of RD. Note that ES936 suppressed the effect 
of CA but did not increase the sensitivity of the cells to RD. This probably indicates that the 
small amount of NQO1 in B16BL6 cells in a basal state (Figure 1A) hardly contributes to RD 
resistance. 
 
CA prevents RD-induced apoptosis of melanocytes 
We studied whether RD cytotoxicity involves induction of apoptotic cell death, and if so, how 
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CA affects this process. B16BL6 or HEMn-LP/hTERT1 cells were treated with 10 or 50 µM RD 
for 72 h in the absence or presence of 25 µM CA, and the appearance of apoptosis marker 
proteins was examined. RD treatment induced cleavage of caspase 3 and poly ADP ribose 
polymerase (PARP) in HEMn-LP/hTERT1 at both concentrations of RD, and the induction was 
strongly suppressed by addition of CA (Figure 3). In contrast, only weak induction of cleavage 
of caspase 3 and PARP was observed in B16BL6 even in the presence of 50 µM RD, which was 
completely abrogated by CA. The difference in the rate of apoptosis induction between B16BL6 
and HEMn-LP/hTERT1 cells may partly explain the slight difference in their RD sensitivity 
(IC50: 230 µM versus 178 µM), or may simply reflect a difference in the mode of death between 
the two cell lines. 
 
Establishment of a cell line showing conditional NQO1 expression in an auxin-dependent 
manner 
To demonstrate the involvement of NQO1 in detoxification of RD more specifically, we 
established a cell line conditionally expressing NQO1 from B16BL6, making use of an 
auxin-inducible degron (AID) system (Nishimura et al. 2009). In the AID system, the 
plant-derived F-box protein TIR1 and the protein of interest fused with AID are co-expressed. 
Addition of the plant hormone auxin induces TIR1-dependent rapid ubiquitination of AID 
followed by proteasome-mediated degradation of the fusion protein usually within 1 h. This 
facilitates far more prompt shut-off of the target protein in comparison with a 
transcription-repression-based system. We inserted human NQO1 cDNA into the pAID1.1N 
plasmid and isolated stable clones from B16BL6. A clone showing high TIR1 and AID-NQO1 
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expression was selected and confirmed to show auxin-mediated degradation of AID-NQO1 
(B16BL6/pAO1). B16BL6/pAO1 constitutively expresses AID-NQO1 from the 
cytomegalovirus promoter at a level comparable to endogenous NQO1 induced by treatment 
with 10 µM CA (Figure 4A). AID-NQO1 quickly disappears after treatment with a synthetic 
auxin analogue, 1-naphthaleneacetic acid (1-NAA), for 1 h. We measured the growth of 
B16BL6/pAO1 after RD treatment. As expected, B16BL6/pAO1 was much more resistant to 
RD (IC50 > 2000 µM, Figure 4B) than its parental line B16BL16 (IC50 = 230 µM). Remarkably, 
addition of 1-NAA reduced the IC50 of RD from >2000 µM to 272 µM (Figure 4B), to a degree 
resembling that of the parental line. Another independent clone gave essentially the same results 
(data not shown). These observations strongly indicate that expression of NQO1 is almost solely 
responsible for CA-mediated attenuation of RD cytotoxicity. 
 
CA does not interfere with the inhibitory effect of RD on melanin synthesis 
We next examined whether CA hinders the inhibitory effect of RD on melanin synthesis. 
B16BL6 cells were cultured for 72 h in the presence of 2 or 10 µM RD with or without 0.5 µM 
CA. Cytotoxicity of both RD and CA is minimal under these conditions (Figure 1B, 2A). The 
pellets of cells treated with 10 µM RD were markedly lighter in color than those of untreated 
control cells or cells treated with 2 µM RD (Figure 5A). Addition of CA did not notably affect 
the lightening induced by RD. We quantified the melanin concentration by measuring the 
absorbance of a cell lysate at 500 nm (Figure 5B). The melanin level was reduced to 
approximately 50% with 2 μM RD treatment, and to 30% with 10 μM RD treatment. Again, 
addition of CA did not significantly change the inhibitory effect of RD.  
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Effect of RD and CA on melanin production and melanocyte survival in a 3D skin model 
To investigate the effect of CA on RD cytotoxicity against melanocytes in a setting closer to in 
vivo conditions, we utilized a commercial 3D culture model of human skin. The culture model 
was incubated for 10 or 14 days in medium containing 2 or 10 µM RD with or without 25 µM 
CA. In the control culture, obvious darkening was observed, reflecting proliferation of 
melanocytes and ongoing melanin synthesis during this period (Figure 5C). Addition of RD 
suppressed this darkening in a dose-dependent manner, and CA did not have any apparent effect 
on this suppression (Figure 5C). Microscopy of the immunostained sections revealed that most 
of the melan-A-positive cells in the basal layer, representing melanocytes, disappeared after 
treatment with 10 µM RD in the absence of CA (Figure 5D). This implies that suppression of 
darkening by RD alone may involve permanent elimination of melanin-producing cells. In 
contrast, about 60% of the melan-A-positive cells persisted in the sample treated simultaneously 
with RD and CA, in comparison with the control. Our observations suggest that CA also 
attenuates the cytotoxicity of RD without notably retarding the suppression of melanogenesis by 
RD under in vivo-mimicking conditions. 
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Discussion 
Our present results clearly demonstrated that forced expression of NQO1 mitigates the 
cytotoxicity of RD without notably affecting the inhibition of melanin synthesis. An obvious 
explanation for this is that NQO1 reduces quinone compounds originating from RD to less toxic 
catechol forms. One immediate metabolite of RD produced by tyrosinase oxidation is reported 
to be RD-quinone (Ito et al. 2014), which would be reduced to RD-catechol (hydroxy-RD) by 
NQO1. While the relative cytotoxicity of RD-quinone and RD-catechol has not been directly 
measured due to instability of the former (Sasaki et al. 2014; Kasamatsu et al. 2014; Okura et al. 
2015), it seems reasonable to assume that highly reactive RD-quinone may have higher 
cytotoxicity (Ito et al. 2015), and therefore that its reduction may imply detoxification. Other 
secondary quinones might also partly contribute to the cytotoxicity of RD (Ito et al. 2015). This 
issue remains to be clarified in a future study. 
The KEAP1/NRF2 system up-regulates a set of genes encoding phase II detoxification enzymes 
other than NQO1. These include GCLM and GCLC, whose products constitute 
glutamate-cysteine ligase, a rate-limiting enzyme for GSH production, as well as several genes 
encoding glutathione S-transferases (Malhotra et al. 2010; Suzuki et al. 2013). Since 
conjugation of GSH to quinone is regarded as a first line of cellular defense against quinone 
toxicity, it would be reasonable to assume that NRF2/KEAP1 activation may contribute to 
detoxification of RD by increasing not only NQO1, but also GSH within cells and activating 
conjugation. In the present study, however, forced expression of NQO1 alone was sufficient to 
decrease RD toxicity to almost the same level as that by CA-mediated detoxification. This 
observation suggests that NRF2 targets other than NQO1 play minor or redundant roles in 
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resistance to RD. 
NQO1 is also reported to modulate cell growth by stabilizing the tumor suppressor p53 (Asher 
et al. 2001; Asher et al. 2005). Although we have not examined the involvement of p53 in 
growth recovery after RD treatment, if NQO1 overexpression positively regulates p53 function 
by stabilizing it, that would result in either cell cycle arrest or activation of apoptosis, and be 
observed as growth inhibition of the cell population. However, this appears to contradict what 
we observed, and accordingly we do not consider p53 to play a major role in mitigation of RD 
toxicity by NQO1. 
An allelic variant of NQO1 with essentially no enzymatic activity, NQO1*2 (NQO1P187S, 
rs1800566 in dbSNP, Traver et al. 1992), is reported to exist at a high frequency, especially in 
Asian populations (allele frequency = 0.4187 in Asians versus 0.2107 in Europeans) according 
to the phase 3 May 2013 call set of the 1000 Genome Project (1000 Genomes Project 
Consortium et al. 2012). Whereas the amount of NQO1 in the basal state hardly contributed to 
growth recovery after RD treatment in our experiment using the B16BL6 mouse melanoma cell 
line, it might exert some influence in human skin in vivo, considering the varying degree of 
basal expression of NQO1 in different tissues (Siegel et al. 2012). While it is clear that the 
NQO1 genotype is not the sole determinant, since only 2% of RD consumers developed 
leukoderma (Nishigori et al. 2015), it would be of interest to investigate the genetic background 
of RD-induced leukoderma. In fact, for some antitumor quinones on which NQO1 may act as a 
bioactivator, polymorphism of NQO1 is reportedly associated with response to chemotherapy 
(Fagerholm et al. 2008; Jamieson et al. 2011). It should also be noted that application of CA 
may not be effective for individuals with homozygous NQO1-null alleles. 
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Methods 
Materials 
RS-Rhododendrol (RD) was kindly provided by Kanebo Cosmetics Inc. (Tokyo, Japan). 
Carnosic acid (CA), N-phenylthiourea (PTU), sulforaphan, and the NQO1 inhibitor ES936 were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Stock solutions were prepared by 
dissolving the chemicals in DMSO at 4 M (RD), 100 mM (CA), 100 mM (sulforaphan) and 20 
μM (ES936). All other reagents and chemicals were of high grade and commercially available. 
 
Cell culture and media 
All cells were maintained in a humidified atmosphere with 5% CO2 at 37°C. 
A murine melanoma cell line B16BL6 was obtained from RIKEN Cell Bank (Tsukuba, Japan) 
and cultured in RPMI 1640 medium (Thermo Fisher Scientific, Waltham, MA, USA) 
supplemented with 10% FBS. 
Primary cultures of normal human epidermal melanocytes (NHEM) were purchased from 
Kurabo Industries Ltd. (Osaka, Japan) and cultured in Medium 254 containing Human 
Melanocyte Growth Supplement (Kurabo Industries Ltd.), penicillin (100 U/ml), streptomycin 
(100 μg/ml), and 4-amphotericin (250 ng/ml). 
An immortalized human melanocyte line (HEMn-LP/hTERT1) established in our laboratory 
from the commercially available human melanocyte line HEMn-LP (Thermo Fisher Scientific) 
was cultured in DMEM (Thermo Fisher Scientific) supplemented with 1% Human Melanocyte 
Growth Supplement (Thermo Fisher Scientific). 
A three-dimensional human skin model MEL-300-A was purchased from Kurabo Industries Ltd. 
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(Osaka, Japan) and maintained in EPI-100LLMM medium as instructed by the manufacturer. 
 
Cell viability assay 
A Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan), which utilizes water-soluble 
tetrazolium salts, was used to evaluate the proliferation of melanocytes or melanoma cells after 
drug treatment. Cells were seeded into 96-well plates (2000 cells/well) and cultured for 24 h 
prior to treatment with RD and/or CA. After the treatment, medium in each well was replaced 
with 100 µl of drug-free fresh medium and 10 μl of Cell Counting Kit-8 solution, incubated for 
an additional 1-2 h, and the absorbance of each well at 450 nm was measured with the use of a 
Multiskan Spectrum spectrophotometer (Thermo Fisher Scientific). 
 
Protein preparation and immunoblotting 
Cells at 80–90% confluence were washed twice with ice-chilled PBS, treated with 10% TCA for 
30 min on ice, and then scraped off into a tube. The cell pellet was washed once with deionized 
water and lysed in 9 M urea, 2% Triton X-100 and 1% DTT. Protein concentration was 
measured with a BCA protein assay kit (Merck Millipore, Billerica, MA, USA) before addition 
of DTT. Protein samples were electrophoresed on 4–12% NuPAGE Bis-Tris gels (Thermo 
Fisher Scientific) for 30 min at 200 V and then transferred onto polyvinylidene fluoride transfer 
membranes (Pall Corporation, Port Washington, NY, USA). The membranes were blocked with 
5% non-fat dried milk (#9999, Cell Signaling Technology) in 1 × TBS-T for 1 h at room 
temperature and then immunoreacted with an appropriate primary antibody overnight at 4°C 
and with a HRP-conjugated secondary antibody (GE Healthcare Life Sciences, 
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Buckinghamshire, UK) for 1 h at room temperature. Signals were detected with ECL prime 
detection reagents (GE Healthcare Life Sciences) and ChemiDoc XRS (Bio-Rad Laboratories, 
Hercules, CA, USA). The intensity of the detected signals was quantified using ImageJ/Fiji 
software (Schindelin et al. 2012) and normalized against the β-actin signal. Antibodies against 
NRF2 (#8882, 1:500 for immunoblotting), NQO1 (#3187, 1:1000), cleaved caspase 3 (#9661S, 
1:1000) and PARP1 (#9544S, 1:1000) were from Cell Signaling Technology (Danvers, MA, 
USA). The antibody against β-actin was from Sigma-Aldrich (#A2228, 1:1000). Electrophoresis 
and immunoblotting were repeated at least three times with independent sample preparations 
and confirmed to be reproducible. 
 
Stable overexpression of NQO1 in B16BL6 cells  
Total RNA was prepared from a human melanoma cell line A7, in which KEAP1/NRF2 is 
constitutively activated (Miura et al. 2013). cDNA was synthesized with oligo(dT) and 
SuperScript III (Thermo Fisher Scientific), and NQO1 cDNA was amplified by PCR using KOD 
Plus NEO DNA polymerase (Toyobo, Osaka, Japan) and a specific primer pair,  
5′-GGGGGGATATCATGGTCGGCAGAAGAGCACTGAT-3′ and 
5′-GGGGGACGCGTTCATTTTCTAGCTTTGATCTGGT-3′. The ends of the amplified cDNA 
fragment were digested with EcoRV and MluI, subcloned into the pAID-N1.1 vector (BioROIS, 
Mishima, Japan), and termed pAO1. The sequence of the entire length of the inserted NQO1 
cDNA was verified using a 3500 Genetic Analyzer (Thermo Fisher Scientific). pAO1 was 
linearized with AflII to increase the integration efficiency, and transfected into B16BL6 cells 
using Lipofectamine 3000 (Thermo Fisher Scientific) in accordance with the manufacturer’s 
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protocol. Stably transfected cells were selected in medium containing 1000 μg/ml G418 for 7 
days, and several clones were isolated by limiting dilution. The clones were examined for 
expression and 1-NAA-dependent degradation of the AID-NQO1 fusion protein by 
immunoblotting. 
 
Measurement of melanin content  
Melanin was quantified spectroscopically as reported previously (Yokota et al. 1998). Three 
hundred thousand cells were plated on a 60-mm plastic dish. After attachment, the cells were 
treated with 2 or 10 µM RD and/or 0.5 µM CA for 72 h. The cells were then harvested by 
trypsinization, fixed with 5% TCA for 90 min, washed with ethanol-ether (3:1) and ether, and 
dissolved in 0.5 ml of Soluene-350 (PerkinElmer, Inc., Waltham, MA, USA) at 80°C for 1 h. 
The absorbance at 500 nm was measured with a Multiskan Spectrum instrument (Thermo Fisher 
Scientific). 
 
Evaluation of melanocyte viability and melanogenesis in 3D human skin models 
The human skin model was cultured in medium containing 2 or 10 µM RD with or without 0.5 
µM CA for 10 or 14 days with a change of medium every other day. After the treatment, 
photographs were taken for visual inspection of melanogenesis. For microscopic observation of 
melanocytes in the 3D model, samples were fixed with 4% formaldhyde after the 10 days of 
treatment, and embedded in paraffin. Four-micrometer-thick sections were cut and stained with 
hematoxylin and eosin. The sections were then immunostained using anti-melan A, following a 
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procedure described previously (Watanabe et al. 2013). The extent of immunohistochemical 
reactivity was estimated by light microscopy. 
 
Statistical analysis 
Data are presented as the mean ± SEM. Statistical significance of differences in the mean was 
assessed by Welch’s t-test using Microsoft Excel (Microsoft, Seattle, WA, USA). P <0.05 was 
considered to indicate statistical significance. Logistic function was fitted to the cell 
proliferation data points with the least squares estimates of the parameters. IC50 values were 
calculated from the fitted function. 
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Figure legends 
Figure 1. CA activates the KEAP1/NRF2 transcriptional program in a dose-dependent manner 
within the range of least toxicity. (A) BL16BL6 mouse melanoma cells were treated with CA at 
several different concentrations for 24 h, and the levels of NRF2 and NQO1 protein were 
examined with immunoblotting. Sulforaphane was used as a positive control (Zhang et al. 1992). 
(B) B16BL6 cells and human immortalized melanocytes (HEMn-LP/hTERT1) were treated 
with increasing concentrations of CA for 24 h, and the cell growth was assessed with a 
water-soluble tetrazolium salt-based assay (see Materials and Methods). The results are 
expressed as mean ± SEM of relative cell numbers relative to those of the untreated control in 
triplicate experiments. 
 
Figure 2. CA mitigates the cytotoxicity of RD by NQO1 activation. (A) B16BL6, 
HEMn-LP/hTERT1 or normal human melanocytes (NHEM) were treated with various 
concentrations of RD with or without 0.5 µM CA for 24 h, and cell growth was measured. In 
B16BL6, 10 µM CA induced further resistance to RD. (B) B16BL6 cells were treated with RD 
at concentrations of 0 to 2 mM and 0.5 µM CA with or without 100 nM ES936 for 24 h. ES936 
abolished most of the cytoprotective effect of CA on RD-treated cells. Results are expressed as 
mean ± SEM of triplicate experiments. 
 
Figure 3. CA prevents RD-induced apoptosis of melanocytes. B16BL6 or HEMn-LP/hTERT1 
were treated with 10 or 50 µM RD with or without 25 µM of CA for 72 h. Extracts of the 
treated cells were examined for cleavage of caspase-3 and PARP1. 
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Figure 4. Ectopic expression of NQO1 mitigates the cytotoxicity of RD. (A) Stable expression 
of AID-NQO1 in B16BL6/pAO1. B16BL6 or B16BL6/pAO1 cells were treated with increasing 
concentrations of CA and/or 0.5 µM auxin for 24 h, and examined for NQO1 expression using 
immunoblotting. B16BL6/pAO1 constitutively expressed the AID-NQO1 fusion protein to an 
extent comparable with that of endogenous NQO1 in the parental B16BL6 induced by treatment 
with 10 µM CA. AID-NQO1 promptly disappeared after addition of 0.5 mM 1-NAA. (B) 
B16BL6/pAO1 cells were treated with RD at concentrations of 0 to 2 mM with or without 0.5 
mM 1-NAA for 24 h, and cell proliferation was assessed. Results are expressed as mean ± SEM 
of triplicate experiments. 
 
Figure 5. CA treatment does not notably hinder the suppressive effect of RD on melanogenesis 
while increasing the survival of melanocytes against RD in a 3D culture model. (A) B16BL6 
cell pellets after RD and/or CA treatment. B16BL6 cells were cultured for 72 h in the presence 
of 2 or 10 µM RD with or without 0.5 µM CA. PTU, an established tyrosinase inhibitor with a 
non-competitive mechanism (Chang 2009), was used as a positive control. (B) Relative amounts 
of melanin in BL16BL6 cells after RD and/or CA treatment. Absorbance of extracts of the 
treated cells at 500 nm was measured with a spectrophotometer. Results are expressed as mean 
± SEM of triplicate experiments. (**P <0.01, ***P <0.001, Welch’s t-test). (C) Photographs of 
the 3D human skin model after the treatment. The skin model was placed in 6-well plates and 
cultured in medium containing 10 µM RD or 2.0 µM RD with or without 0.5 µM CA for 14 
days. Medium containing the drug was replaced every other day. (D) Representative 
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microscopic images of melan-A-immunostained sections of the 3D skin model after treatment 
with RD and CA for 10 days. 
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Supplementary Figure legend 
Figure S1 Expression of NRF2 and NQO1 in B16BL6 cells after RD, CA or ES936 treatment. 
B16BL6 mouse melanoma cells were treated with a combination of RD (0.2 mM), CA (0.5 µM) 
or ES936 (100 µM) for 24 h, and the levels of NRF2 and NQO1 protein were examined by 
immunoblotting. Signal intenisites were normalized against the β-actin signal. Note that 0.2 mM 
RD resulting in 50 % growth inhibition induced a much weaker level of NRF2 or NQO than 0.5 
µM CA resulting in no significant growth inhibition. 
 
